Eton Pharmaceuticals (ETON) vs Rapport Therapeutics (RAPP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Eton Pharmaceuticals (ETON) has outperformed Rapport Therapeutics (RAPP) over the past year, gaining 159.5% versus a gain of 16.7%. Eton Pharmaceuticals is the larger company by market cap ($1.57 billion vs $1.48 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ETON | RAPP |
|---|---|---|
| Share price | $54.88 | $30.86 |
| Market cap | $1.57B | $1.48B |
| 1-day change | +0.20% | -0.93% |
| YTD return | +224.54% | +1.71% |
| 1-year return | +159.48% | +16.72% |
| 5-year return | +953.36% | — |
| P/E ratio (TTM) | 137.20 | — |
| Forward P/E | 21.27 | — |
| EPS (TTM) | $0.40 | $-3.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $66.37 | $52.93 |
| 52-week low | $14.27 | $23.75 |
| Distance from 52-week high | -17.31% | -41.70% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +29.37% | +104.28% |
| Average volume | 603.39K | 370.01K |
| Shares outstanding | 28.58M | 47.98M |
| Employees | 44 | 84 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ETON has outperformed RAPP by 142.8 percentage points over the past year.
About Eton Pharmaceuticals
ETON stock →Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1.
Healthcare · Drug Manufacturers - Specialty & Generic · 44 employees
About Rapport Therapeutics
RAPP stock →Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder.
Healthcare · Biotechnology · 84 employees
ETON vs RAPP FAQ
Which is bigger, Eton Pharmaceuticals or Rapport Therapeutics?
Eton Pharmaceuticals (ETON) is larger, with a market capitalization of $1.57B compared with $1.48B for Rapport Therapeutics (RAPP).
Which stock has performed better over the past year, ETON or RAPP?
ETON returned +159.48% over the past 12 months, compared with +16.72% for RAPP (price return, excluding dividends). Past performance does not predict future results.
Are Eton Pharmaceuticals and Rapport Therapeutics in the same industry?
Both are in the Healthcare sector, but in different industries: Drug Manufacturers - Specialty & Generic for Eton Pharmaceuticals and Biotechnology for Rapport Therapeutics.